DAWN Taps Markets After ASCO23 Update
Insights - Day One (DAWN) announced a $150M raise priced at $13/share after presenting additional data at ASCO 2023. Importantly, the company formed a regulatory pathway in … Continue Reading
Premium: Read NowInsights
PDS Bio Unconfirmed Responses Don’t Give It Much Differentiation From SoC
Insights - PDS Bio dropped 40% on the ASCO presentation after there were confusion around their confirmed/unconfirmed response rate. The company held a conference call (read transcript here) … Continue Reading
Premium: Read Now
Highlights of ASCO 2023 Abstracts
Insights - A few insights/notes from the ASCO abstracts that were released Thursday afternoon. ADCs Stay Winning ELEV’s ADC Validating Claudin18.2 TargetThe biggest mover from ASCO abstract release seems … Continue Reading
Premium: Read Now
Oral Obesity Treatments Making Waves
Insights - Biotech is bouncing back from the FTC news that raised concerns over M&A activity (read details here). Today, weight loss names are in the spotlight and … Continue Reading
Read Now
FTC Pauses Biotech Rally, But Show Must Go On
Insights - The biotech rally has been put on pause on news of the FTC lawsuit to block Amgen’s (AMGN) acquisition of Horizon (HZNP). Investors are now … Continue Reading
Read NowLilly’s Donanemab Data a Big Leap for Alzheimer’s
Insights - Eli Lilly (LLY) lifted the bio market yesterday after their amyloid targeting therapy, donanemab, showed that it slowed cognitive and functional decline in a Phase … Continue Reading
Premium: Read Now
Big Pharma in Shopping Mode for 2023
Insights - 2023 has already brought several high-profile M&A deals, as pharma giants are sitting on an estimated $272B of cash and looking to spend it. As … Continue Reading
Premium: Read Now